Test Code MAC1 Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Reporting Name
Myelopathy, Autoimm/Paraneo, CSFPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Evaluating patients with suspected autoimmune myelopathy, myelitis, and paraneoplastic myelopathy using spinal fluid specimens
Method Name
MCI1: Medical Interpretation
AGN1C, AGNTC, AMPHC, APHTC, ANN1C, AN1TC, ANN2C, AN2TC, ANN3C, AN3TC, APBIC, APBTC, CRMTC, DPPTC, GABIC, GFAIC, GFATC, GL1IC, GL1TC, NCDIC, NCDTC, NIFIC, NIFTC, PCA1C, PC1TC, PCA2C, PC2TC, SP7IC, SP7TC, T46IC, T46TC: Indirect Immunofluorescence Assay (IFA)
GD65C: Radioimmunoassay (RIA)
CRMWC: Western Blot (WB)
AGNBC, AMIBC, AN1BC, AN2BC, PC1BC: Immunoblot (IB)
NMOFC, NMOTC: Flow Cytometry (FCM)
APBCC, DPPCC, GABCC, GFACC, GL1CC, NCDCC, AINCC, NFLCC, NFHCC, SP7CC, T46CC: Cell Binding Assay (CBA)
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, see Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number, the duplicate test will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
Specimen Required
Container/Tube: Sterile vial
Preferred: Collection vial number 1
Acceptable: Any collection vial
Specimen Volume: 4 mL
Specimen Type
CSFSpecimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Test ID |
Reporting name |
Methodology* |
Reference value |
MCI1 |
Autoimmune Myelopathy Interp, CSF |
Medical interpretation |
Interpretive report |
AMPHC |
Amphiphysin Ab, CSF |
IFA |
Negative |
AGN1C |
Anti-Glial Nuclear Ab, Type 1 |
IFA |
Negative |
ANN1C |
Anti-Neuronal Nuclear Ab, Type 1 |
IFA |
Negative |
ANN2C |
Anti-Neuronal Nuclear Ab, Type 2 |
IFA |
Negative |
ANN3C |
Anti-Neuronal Nuclear Ab, Type 3 |
IFA |
Negative |
APBIC |
AP3B2 IFA, CSF |
IFA |
Negative |
CRMWC |
CRMP-5-IgG Western Blot, CSF |
WB |
Negative |
DPPCC |
DPPX Ab CBA, CSF |
CBA |
Negative |
GABCC |
GABA-B-R Ab CBA, CSF |
CBA |
Negative |
GD65C |
GAD65 Ab Assay, CSF |
RIA |
≤0.02 nmol/L Reference values apply to all ages. |
GFAIC |
GFAP IFA, CSF |
IFA |
Negative |
GL1IC |
mGluR1 Ab IFA, CSF |
IFA |
Negative |
NCDIC |
Neurochondrin IFA, CSF |
IFA |
Negative |
NIFIC |
NIF IFA, CSF |
IFA |
Negative |
NMOFC |
NMO/AQP4 FACS, CSF |
FCM |
Negative |
PCA1C |
Purkinje Cell Cytoplasmic Ab Type 1 |
IFA |
Negative |
PCA2C |
Purkinje Cell Cytoplasmic Ab Type 2 |
IFA |
Negative |
SP7IC |
Septin-7 IFA, CSF |
IFA |
Negative |
T46IC |
TRIM46 IFA, CSF |
IFA |
Negative |
Reflex Information:
Test ID |
Reporting name |
Methodology* |
Reference value |
AGNBC |
AGNA-1 Immunoblot, CSF |
IB |
Negative |
AGNTC |
AGNA-1 Titer, CSF |
IFA |
<1:2 |
AINCC |
Alpha Internexin CBA, CSF |
CBA |
Negative |
AMIBC |
Amphiphysin Immunoblot, CSF |
IB |
Negative |
AN1BC |
ANNA-1 Immunoblot, CSF |
IB |
Negative |
AN1TC |
ANNA-1 Titer, CSF |
IFA |
<1:2 |
AN2BC |
ANNA-2 Immunoblot, CSF |
IB |
Negative |
AN2TC |
ANNA-2 Titer, CSF |
IFA |
<1:2 |
AN3TC |
ANNA-3 Titer, CSF |
IFA |
<1:2 |
APBCC |
AP3B2 CBA, CSF |
CBA |
Negative |
APBTC |
AP3B2 IFA Titer, CSF |
IFA |
<1:2 |
APHTC |
Amphiphysin Ab Titer, CSF |
IFA |
<1:2 |
CRMTC |
CRMP-5-IgG Titer, CSF |
IFA |
<1:2 |
DPPTC |
DPPX Ab IFA Titer, CSF |
IFA |
<1:2 |
GABIC |
GABA-B-R Ab IF Titer Assay, CSF |
IFA |
<1:2 |
GFACC |
GFAP CBA, CSF |
CBA |
Negative |
GFATC |
GFAP IFA Titer, CSF |
IFA |
<1:2 |
GL1CC |
mGluR1 Ab CBA, CSF |
CBA |
Negative |
GL1TC |
mGluR1 Ab IFA Titer, CSF |
IFA |
<1:2 |
NCDCC |
Neurochondrin CBA, CSF |
CBA |
Negative |
NCDTC |
Neurochondrin IFA Titer, CSF |
IFA |
<1:2 |
NFHCC |
NIF Heavy Chain CBA, CSF |
CBA |
Negative |
NIFTC |
NIF IFA Titer, CSF |
IFA |
<1:2 |
NFLCC |
NIF Light Chain CBA, CSF |
CBA |
Negative |
NMOTC |
NMO/AQP4 FACS Titer, CSF |
FCM |
<1:2 |
PC1BC |
PCA-1 Immunoblot, CSF |
IB |
Negative |
PC1TC |
PCA-1 Titer, CSF |
IFA |
<1:2 |
PC2TC |
PCA-2 Titer, CSF |
IFA |
<1:2 |
SP7CC |
Septin-7 CBA, CSF |
CBA |
Negative |
SP7TC |
Septin-7 IFA Titer, CSF |
IFA |
<1:2 |
T46CC |
TRIM46 CBA, CSF |
CBA |
Negative |
T46TC |
TRIM46 IFA Titer, CSF |
IFA |
<1:2 |
*Methodology Abbreviations:
Immunofluorescence assay (IFA)
Cell-binding assay (CBA)
Flow cytometry (FCM)
Radioimmunoassay (RIA)
Immunoblot (IB)
Western blot (WB)
Neuron-restricted patterns of IgG staining that do not fulfill criteria for ANNA-1, ANNA-2, ANNA-3, CRMP-5-IgG, PCA-1, or PCA-2 may be reported as "unclassified anti-neuronal IgG." Complex patterns that include nonneuronal elements may be reported as "uninterpretable."
Interpretation
A positive result is consistent with a diagnosis of autoimmune myelopathy in the appropriate clinical context.
Day(s) Performed
Profile tests: Monday through Sunday; Reflex tests: Varies
Report Available
8 to 12 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255 x 16
86053
86341
84182
84182 AGNBC (if appropriate)
86256 AGNTC (if appropriate)
86255 AINCC (if appropriate)
84182 AMIBC (if appropriate)
84182 AN1BC (if appropriate)
86256 AN1TC (if appropriate)
84182 AN2BC (if appropriate)
86256 AN2TC (if appropriate)
86256 AN3TC (if appropriate)
86255 APBCC (if appropriate)
86256 APBTC (if appropriate)
86256 APHTC (if appropriate)
86256 CRMTC (if appropriate)
86256 DPPTC (if appropriate)
86256 GABIC (if appropriate)
86255 GFACC (if appropriate)
86256 GFATC (if appropriate)
86255 GL1CC (if appropriate)
86256 GL1TC (if appropriate)
86255 NCDCC (if appropriate)
86256 NCDTC (if appropriate)
86255 NFHCC (if appropriate)
86255 NFLCC (if appropriate)
86256 NIFTC (if appropriate)
86053 NMOTC (if appropriate)
84182 PC1BC (if appropriate)
86256 PC1TC (if appropriate)
86256 PC2TC (if appropriate)
86255 SP7CC (if appropriate)
86256 SP7TC (if appropriate)
86255 T46CC (if appropriate)
86256 T46TC (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
MAC1 | Myelopathy, Autoimm/Paraneo, CSF | 94353-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
61515 | GABA-B-R Ab CBA, CSF | 93426-5 |
38325 | NMO/AQP4-IgG FACS, CSF | 46718-3 |
64927 | mGluR1 Ab IFA, CSF | 94361-3 |
64934 | DPPX Ab CBA, CSF | 94283-9 |
605156 | GFAP IFA, CSF | 94360-5 |
605128 | Autoimmune Myelopathy Interp, CSF | 69048-7 |
606965 | NIF IFA, CSF | 96490-8 |
615862 | AP3B2 IFA, CSF | 101907-4 |
615866 | Neurochondrin IFA, CSF | 101451-3 |
615874 | Septin-7 IFA, CSF | 101464-6 |
616446 | TRIM46 Ab IFA, CSF | 103843-9 |
89079 | AGNA-1, CSF | 90827-7 |
5906 | Amphiphysin Ab, CSF | 90815-2 |
3852 | ANNA-1, CSF | 44768-0 |
7472 | ANNA-2, CSF | 56959-0 |
21633 | ANNA-3, CSF | 90836-8 |
3988 | PCA-1, CSF | 90841-8 |
21632 | PCA-2, CSF | 90843-4 |
21747 | CRMP-5-IgG Western Blot, CSF | 53707-6 |
21702 | GAD65 Ab Assay, CSF | 94359-7 |
618901 | IFA Notes | 48767-8 |
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
MCI1 | Autoimmune Myelopathy Interp, CSF | No | Yes |
AMPHC | Amphiphysin Ab, CSF | No | Yes |
AGN1C | Anti-Glial Nuclear Ab, Type 1 | No | Yes |
ANN1C | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
ANN2C | Anti-Neuronal Nuclear Ab, Type 2 | No | Yes |
ANN3C | Anti-Neuronal Nuclear Ab, Type 3 | No | Yes |
APBIC | AP3B2 IFA, CSF | No | Yes |
CRMWC | CRMP-5-IgG Western Blot, CSF | Yes | Yes |
DPPCC | DPPX Ab CBA, CSF | No | Yes |
GABCC | GABA-B-R Ab CBA, CSF | No | Yes |
GD65C | GAD65 Ab Assay, CSF | Yes | Yes |
GFAIC | GFAP IFA, CSF | No | Yes |
GL1IC | mGluR1 Ab IFA, CSF | No | Yes |
NCDIC | Neurochondrin IFA, CSF | No | Yes |
NIFIC | NIF IFA, CSF | No | Yes |
NMOFC | NMO/AQP4 FACS, CSF | Yes | Yes |
PCA1C | Purkinje Cell Cytoplasmic Ab Type 1 | No | Yes |
PCA2C | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
SP7IC | Septin-7 IFA, CSF | No | Yes |
T46IC | TRIM46 Ab IFA, CSF | No | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AGNBC | AGNA-1 Immunoblot, CSF | No | No |
AINCC | Alpha Internexin CBA, CSF | No | No |
AMIBC | Amphiphysin Immunoblot, CSF | No | No |
AN1BC | ANNA-1 Immunoblot, CSF | No | No |
AN2BC | ANNA-2 Immunoblot, CSF | No | No |
DPPTC | DPPX Ab IFA Titer, CSF | No | No |
GABIC | GABA-B-R Ab IF Titer Assay, CSF | No | No |
GFACC | GFAP CBA, CSF | No | No |
GFATC | GFAP IFA Titer, CSF | No | No |
GL1CC | mGluR1 Ab CBA, CSF | No | No |
GL1TC | mGluR1 Ab IFA Titer, CSF | No | No |
NFHCC | NIF Heavy Chain CBA, CSF | No | No |
NIFTC | NIF IFA Titer, CSF | No | No |
NFLCC | NIF Light Chain CBA, CSF | No | No |
NMOTC | NMO/AQP4 FACS Titer, CSF | No | No |
PC1BC | PCA-1 Immunoblot, CSF | No | No |
AGNTC | AGNA-1 Titer, CSF | No | No |
AN1TC | ANNA-1 Titer, CSF | No | No |
AN2TC | ANNA-2 Titer, CSF | No | No |
AN3TC | ANNA-3 Titer, CSF | No | No |
APBCC | AP3B2 CBA, CSF | No | No |
APBTC | AP3B2 IFA Titer, CSF | No | No |
APHTC | Amphiphysin Ab Titer, CSF | No | No |
CRMTC | CRMP-5-IgG Titer, CSF | No | No |
NCDCC | Neurochondrin CBA, CSF | No | No |
NCDTC | Neurochondrin IFA Titer, CSF | No | No |
PC1TC | PCA-1 Titer, CSF | No | No |
PC2TC | PCA-2 Titer, CSF | No | No |
SP7CC | Septin-7 CBA, CSF | No | No |
SP7TC | Septin-7 IFA Titer, CSF | No | No |
T46CC | TRIM46 Ab CBA, CSF | No | No |
T46TC | TRIM46 Ab IFA Titer, CSF | No | No |
Testing Algorithm
If the indirect immunofluorescence assay (IFA) pattern suggests anti-glial nuclear antibody (AGNA-1), then the AGNA-1 immunoblot and AGNA-1 IFA titer will be performed at an additional charge.
If the IFA pattern suggests amphiphysin antibody, then the amphiphysin immunoblot and amphiphysin IFA titer will be performed at an additional charge.
If the IFA pattern suggests anti-neuronal nuclear antibody type 1 (ANNA-1), then the ANNA-1 immunoblot, ANNA-1 IFA titer, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-2 antibody, then the ANNA-2 immunoblot, ANNA-2 IFA titer, and ANNA-1 immunoblot will be performed at an additional charge.
If the client requests or the IFA pattern suggests ANNA-3 antibodies, then the ANNA-3 IFA titer will be performed at an additional charge.
If the IFA pattern suggests adaptor protein 3 beta 2 (AP3B2) antibodies, then the AP3BC cell-binding assay (CBA) and AP3BC IFA titer will be performed at an additional charge.
If the collapsin response-mediator protein 5 (CRMP-5)-IgG Western blot is positive, then the CRMP-5-IgG IFA titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cell cytoplasmic antibody type 1 (PCA-1), then the PCA-1 immunoblot and PCA-1 IFA titer will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then the PCA-2 IFA titer will be performed at an additional charge.
If the gamma-aminobutyric acid B (GABA-B) receptor antibody CBA result is positive, then the GABA-B-receptor antibody IFA titer will be performed at an additional charge.
If the dipeptidyl-peptidase-like protein-6 (DPPX) antibody CBA result is positive, then the DPPX antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then the mGluR1 antibody CBA and mGluR1 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then the GFAP antibody CBA and GFAP antibody IFA titer will be performed at an additional charge.
If the neuromyelitis optica/aquaporin-4-IgG (NMO/AQP4-IgG) fluorescence-activated cell sorting (FACS) screen assay requires further investigation, then the NMO/AQP4-IgG FACS titration assay will be performed at an additional charge.
If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then the alpha internexin CBA, NIF heavy chain CBA, NIF light chain CBA, and NIF antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests neurochondrin antibody, then the neurochondrin antibody CBA and neurochondrin IFA titer will be performed at an additional charge.
If the IFA pattern suggests septin 7 antibody, then the septin 7 CBA and septin 7 IFA titer will be performed at an additional charge.
If the IFA pattern suggests tripartite motif-containing protein 46 (TRIM46) antibody, then the TRIM46 antibody CBA and TRIM46 IFA titer will be performed at an additional charge.
For more information see:
Autoimmune/Paraneoplastic Myelopathy Evaluation Algorithm-Spinal Fluid
Central Nervous System Demyelinating Disease Diagnostic Algorithm